

# Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial

Belén Pastor-Villaescusa, PhD,<sup>a,b</sup> M. Dolores Cañete, PhD,<sup>c</sup> Javier Caballero-Villarraso, PhD,<sup>d</sup> Raúl Hoyos, MD,<sup>e</sup> Miriam Latorre, MS,<sup>f,g</sup> Rocío Vázquez-Cobela, PhD,<sup>h</sup> Julio Plaza-Díaz, PhD,<sup>a,b</sup> José Maldonado, MD, PhD,<sup>i</sup> Gloria Bueno, MD, PhD,<sup>b,g</sup> Rosaura Leis, MD, PhD,<sup>b,h</sup> Ángel Gil, PhD,<sup>a,b,j</sup> Ramón Cañete, MD, PhD,<sup>b,k</sup> Concepción M. Aguilera, PhD<sup>a,b,j</sup>

abstract

**OBJECTIVES:** Metformin has shown its effectiveness in treating obesity in adults. However, little research has been conducted in children, with a lack of attention on pubertal status. The objectives were to determine whether oral metformin treatment reduces BMI z score, cardiovascular risk, and inflammation biomarkers in children who are obese depending on pubertal stage and sex.

**METHODS:** This was a randomized, prospective, double-blind, placebo-controlled, multicenter trial, stratified according to pubertal stage and sex, conducted at 4 Spanish clinical hospitals. Eighty prepubertal and 80 pubertal nondiabetic children who were obese aged 7 to 14 years with a BMI >95th percentiles were recruited. The intervention included 1 g/d of metformin versus placebo for 6 months. The primary outcome was a reduction in BMI z score. Secondary outcomes comprised insulin resistance, cardiovascular risk, and inflammation biomarkers.

**RESULTS:** A total of 140 children completed the study (72 boys). Metformin decreased the BMI z score versus placebo in the prepubertal group (−0.8 and −0.6, respectively; difference, 0.2;  $P = .04$ ). Significant increments were observed in prepubertal children treated with metformin versus placebo recipients in the quantitative insulin sensitivity check index (0.010 and −0.007; difference, 0.017;  $P = .01$ ) and the adiponectin–leptin ratio (0.96 and 0.15; difference, 0.81;  $P = .01$ ) and declines in interferon- $\gamma$  (−5.6 and 0; difference, 5.6;  $P = .02$ ) and total plasminogen activator inhibitor-1 (−1.7 and 2.4; difference, 4.1;  $P = .04$ ). No serious adverse effects were reported.

**CONCLUSIONS:** Metformin decreased the BMI z score and improved inflammatory and cardiovascular-related obesity parameters in prepubertal children but not in pubertal children. Hence, the differential response according to puberty might be related to the dose of metformin per kilogram of weight. Further investigations are necessary.



<sup>a</sup>Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology, Center for Biomedical Research, University of Granada, Granada, Spain; <sup>b</sup>CIBER Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Madrid, Spain; <sup>c</sup>PAIDI CTS-329, Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain; <sup>d</sup>Clinical Analysis Services, IMIBIC/Reina Sofía Hospital, Córdoba University, Córdoba, Spain; <sup>e</sup>Pediatric Department and <sup>f</sup>Pediatric Gastroenterology and Nutrition Unit, Virgen de las Nieves University Hospital, Andalusian Health Service, Granada, Spain; <sup>g</sup>Health Sciences Institute in Aragon, Zaragoza, Spain; <sup>h</sup>Pediatric Department, Lozano Blesa University Clinical Hospital, University of Zaragoza, Zaragoza, Spain; <sup>i</sup>Unit of Investigation in Nutrition, Growth and Human Development of Galicia, Pediatric Department, Clinic University Hospital of Santiago, University of Santiago de Compostela, Santiago de Compostela, Spain; <sup>j</sup>Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; and <sup>k</sup>Unit of Pediatric Endocrinology, Reina Sofía University Hospital, Córdoba, Spain

**WHAT'S KNOWN ON THIS SUBJECT:** Although metformin has been shown to be efficacious in treating adults who are diabetic and obese, limited research has been conducted in children, with no attention to potential effects of pubertal development.

**WHAT THIS STUDY ADDS:** The current study is the first randomized controlled trial that assessed the effect of metformin in children who are obese by using a design based on an adequate and separate distribution according to pubertal stage and sex.

**To cite:** Pastor-Villaescusa B, Cañete MD, Caballero-Villarraso J, et al. Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial. *Pediatrics*. 2017;140(1):e20164285

**TABLE 1** Inclusion and Exclusion Criteria

Inclusion Criteria	Exclusion Criteria
BMI greater than the 95th percentile based on the standards of Cole et al <sup>26</sup>	Does not meet the established age
Age 7–14 y	Any previous underlying disease
No underlying disease or a history of pathology	Use of medication with metabolic side effects, such as diuretics, $\beta$ -blockers, $\beta$ -adrenergics, or corticoids
No medical treatment regarding weight control in the previous 12 mo	Cases of monogenic obesity
No participation in a previous trial	Children subjected to long periods of rest
—	Did not sign the informed consent

Overweight and obesity in children are the most challenging health problems to address.<sup>1</sup> Obesity plays an important pathophysiologic role in the development of insulin resistance, dyslipidemia, and hypertension, leading to type 2 diabetes mellitus (T2DM) and a risk of early cardiovascular disease.<sup>2,3</sup> For pediatric patients, several investigations have confirmed that an intensive lifestyle intervention can increase weight loss and insulin sensitivity and reduce the risk of developing T2DM.<sup>4</sup> Nevertheless, a single-strategy lifestyle intervention is not always effective.<sup>5</sup> In addition, efforts have been made to identify effective and safe drugs to manage pediatric obesity. Metformin is an oral antihyperglycemic agent approved by the US Food Drug Administration to treat T2DM in adults and children aged >10 years; it is considered a first-line agent in T2DM by the European Medicines Agency. Significant weight loss induced by metformin has been shown in adults who are obese with or without T2DM.<sup>6</sup> Metformin also produced a decrease in the cardiovascular risk profile<sup>7–10</sup> and inflammatory biomarkers.<sup>7–14</sup>

Nevertheless, evidence regarding the effects of metformin in pediatric obesity is scarce. According to a systematic review and meta-analysis,<sup>15</sup> a reduction in BMI due to metformin compared with the effects of lifestyle interventions alone from 6 to 12 months has been reported in children who are obese. Seven studies have evaluated the effects of metformin (1000–2000 mg/d

for 3–6 months) on such conditions related to obesity in children and/or adolescents who are obese,<sup>16–22</sup> with some promising results obtained. However, randomized controlled trials (RCTs) on this topic did not show an adequate and separate distribution in the study design according to prepubertal and pubertal children. Puberty might act as a potential modifier on the effect of metformin in childhood. Thus, it seems useful to stratify randomization according to Tanner stage and sex to avoid large imbalances between groups in linear growth velocity and other factors associated with pubertal maturation that may affect changes in BMI.<sup>5</sup> We therefore designed an RCT to determine whether metformin would have an effect on reducing the BMI z score and improving cardiovascular and inflammatory risk biomarkers in children who are obese and to assess whether this effect differed depending on pubertal stage and sex.

## METHODS

### Study Design

The study was a multicenter investigation, stratified according to sex and pubertal status (40 prepubertal girls, 40 prepubertal boys, 40 pubertal girls, and 40 pubertal boys). Pubertal stage was determined according to Tanner criteria (standards for pubic hair and genitalia growth in boys; standards for breast and pubic hair development in girls)<sup>23</sup> through a physical examination by the pediatric endocrinologists at the beginning

and the end of the study. This randomized, double-blind, placebo-controlled trial was homogeneously conducted at 4 Spanish clinical hospitals, as previously described.<sup>24</sup> Children were randomly assigned to receive either metformin or placebo for 6 months. Details of the trial protocol and ethics committees have been previously published in *Trials*.<sup>24</sup> The Consolidated Standards of Reporting Trials statement has been considered in the report on study design and results, as well as in the abstract and flow diagram.

### Intervention and Participants

The study subjects comprised 160 patients referred from the Pediatric Endocrinology Unit of the corresponding study centers. Children were invited to participate according to the inclusion criteria described in Table 1.<sup>24</sup> The data are collected in the pediatric outpatient clinics by dietitians. All participants were provided with standardized healthy lifestyle advice at the beginning of a 1-on-1 session according to recommendations for food consumption frequency following the Mediterranean diet criteria and the practice of physical activity based on the AECOSAN NAOS Strategy's NAOS Pyramid (Ministry of Health of the Spanish Government).<sup>25</sup> The data and samples were codified according to each center and subsequently centralized at the Institute of Nutrition and Food Technology "José Mataix" in Granada, Spain.

The participants were assigned to receive metformin or placebo in

accordance with a randomization schedule generated by the Pharmacy Service of the Virgen de las Nieves University Hospital in Granada. MAS 100 version 2.1 software (Glaxo-Wellcome, Madrid, Spain) was used by the Support Consortium to Biomedical Research Network. At each center, 50% of the children were assigned to each group. All research staff was blinded to both the treatment allocation during the time of the study and the data analysis. The patients were instructed to gradually increase their dosage by taking 50 mg twice daily for 10 days, followed by 500 mg twice daily until the end of the intervention. Both treatments were administered during meals. The participants attended an initial trial baseline visit, followed by 2 additional control visits at 2-month intervals, which comprised the assessment of blood pressure and a physical examination. To assess the safety and tolerance of metformin administration, the primary evaluation criteria were the absence of adverse effects, as previously reported.<sup>24</sup>

## Outcomes Measures

### *Anthropometric and Biochemical Analyses*

Anthropometry, blood pressure, and serum concentrations of glucose, insulin, hepatic enzymes, and lipids were measured as previously reported.<sup>24</sup> The quantitative insulin sensitivity check index (QUICKI) and homeostasis model assessment for insulin resistance were also calculated. Obesity was defined according to BMI by using the age- and sex-specific cutoff points proposed by Cole et al<sup>26</sup> (BMI greater than the 95th percentiles).

### *Lifestyle Monitoring*

The dietitians at the centers administered a food frequency questionnaire and a physical activity survey to all participants at the beginning and the end of the trial,

both of which have been validated and normalized.<sup>24</sup> The data collected in the lifestyle habits questionnaires were evaluated according to the healthy lifestyle/diet (HLD) index described by Manios et al<sup>27</sup> to ensure routine quality estimation. The total score on the HLD index ranges from 0 to 48, with higher scores indicating “healthier” dietary/lifestyle patterns. Based on this scoring, they considered 3 groups according to tertiles of the HLD index: unhealthy lifestyle-diet pattern, scores ranging from 1 to 16; moderately HLD pattern, scores ranging from 17 to 32; and HLD pattern, scores ranging from 33 to 48.

### *Inflammation and Cardiovascular Risk Biomarkers*

Specific plasma adipokines, inflammation, and cardiovascular risk biomarkers (adiponectin [coefficient of variation (CV), 12%], leptin (CV, 3%), resistin (CV, 14%), tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) (CV, 10%), monocyte chemoattractant protein-1 (CV, 6%), interleukin-8 (CV, 15%), interferon- $\gamma$  (IFN- $\gamma$ ) (CV, 14%), myeloperoxidase (CV, 14%), total plasminogen activator inhibitor-1 (tPAI-1) (CV, 10%), soluble intercellular adhesion molecule-1 (CV, 5%), soluble vascular adhesion molecule-1 (CV, 6%), and vascular endothelial growth factor (CV, 13%) were analyzed in duplicate by using XMap technology (Luminex Corporation, Austin, TX) and human monoclonal antibodies (Milliplex Map Kit; Millipore, Billerica, MA). Oxidized low-density lipoprotein (CV, 9%) levels from plasma were determined in duplicate via an enzyme-linked immunosorbent assay (Cayman, Ann Arbor, MI) by using a microplate reader (BioTek Synergy HT; BioTek Instruments, Inc, Winooski, VT).

Based on the adiponectin and leptin concentrations, the adiponectin–leptin ratio (ALR) was calculated.

## Sample Size

The sample size was calculated based on BMI as the main outcome, the SD being 2.29 according to the tables of Cole et al,<sup>26</sup> and an expected minimum difference of 2 points of BMI. With an  $\alpha$  error of .05, a  $\beta$  error of .20, and an estimated follow-up loss (dropout) of 20%, 4 groups in total were planned for the study: 2 groups of children who were obese (prepubertal and pubertal) treated with metformin and 2 groups of children who were obese (prepubertal and pubertal) who received placebo. There is a requirement of at least 40 patients per group ( $\times 4$  groups = 160 children).

## Statistical Analysis

Data were analyzed by using SPSS software version 22 for Windows (IBM SPSS Statistics, IBM Corporation, Armonk, NY). All values are expressed as mean  $\pm$  SEM. Variables that were not normally distributed were log-transformed for analysis, and/or values with  $\pm 2$  SD of the mean were removed (without achieving values loss from samples of up to 15%). However, the data are presented as untransformed values to ensure a clear understanding. Differences at baseline per experimental group in each pubertal stage or sex were assessed by using Student’s *t* test or the Mann-Whitney *U* test if the variables were not normally distributed. The data associated with the subjects who dropped out were subsequently excluded from the statistical analysis.

A general linear model for repeated measures was used to determine the outcome changes from baseline to 6 months according to treatment of separated groups of pubertal status (prepubertal and pubertal) and sex (boys and girls). The specific differences between the treatments were assessed by using post hoc Bonferroni tests. The fixed effects included were sex or pubertal stage

(according to analysis group), center, adherence, and the time  $\times$  treatment interaction. Time  $\times$  treatment  $\times$  puberty (or sex) were also estimated when a general linear model for repeated measures was applied to the overall population to analyze the different impact of metformin in variables that presented a significant changes versus placebo in one of the puberty and sex groups. The variables that did not influence the analysis were removed from the model to avoid overadjustments. The variables that had to be adjusted for baseline values were assessed by using an analysis of covariance model.

To check the robustness of the results in relation to the effects on BMI z score according to treatment, a logistic regression model was developed, reporting the odds ratio and 95% confidence intervals.

Differences in dose per kilogram of body weight between prepubertal and pubertal children who were obese were assessed by using an analysis of variance model. Possible differences in adverse effects and clinical signs according to treatment were evaluated by using the Mann-Whitney *U* test, as well as whether adherence differed by treatment in each pubertal stage or sex. Significant changes in the safety parameters (serum creatinine, urea, and liver enzyme activities) by metformin compared with the placebo group were assessed by using an analysis of variance model.

## RESULTS

### Baseline Characteristics of the Participants

Of the 160 white children included, 140 completed the study (72 boys, 68 girls); their age ranged from 6.8 to 15.3 years, translating to 67 prepubertal (Tanner stage I) and 73 pubertal (Tanner stages II–V) children (Fig 1). Twelve participants (7.5%) in the metformin group and 8 (5%) in the placebo group

dropped out. Subjects who dropped out were mainly lost to incomplete follow-up (did not attend at the last visit) and/or they were no longer interested in the study. The baseline demographic, clinical, and biochemical characteristics are summarized in Supplemental Table 4. Children presented with normal fasting blood glucose concentrations according to the International Society for Pediatric and Adolescent Diabetes. In addition, differences at baseline between the intervention groups were found for leptin and  $\gamma$ -glutamyltransferase concentrations in prepubertal participants and for BMI, waist circumference, oxidized low-density lipoprotein, creatinine, and urea in pubertal participants. Regarding sex, higher values were observed at baseline in the placebo group compared with the metformin group for BMI ( $30.2 \pm 0.7$  vs  $28.0 \pm 0.6$ ;  $P = .04$ ) and leptin ( $15.07 \pm 1.0$   $\mu\text{g/L}$  vs  $10.8 \pm 1.0$   $\mu\text{g/L}$ ;  $P = .003$ ) in boys, whereas soluble vascular adhesion molecule-1 was lower in girls in the placebo group ( $696 \pm 33$   $\mu\text{g/L}$  vs  $790 \pm 33$   $\mu\text{g/L}$ ;  $P = .05$ ).

### Anthropometry, Body Composition, and Lifestyle Monitoring

Unlike placebo, metformin treatment decreased the BMI z score ( $P = .04$ ) in the prepubertal group. Moreover, based on a binary logistic regression, the BMI z score was independently associated with metformin treatment (odds ratio, 0.18 [95% confidence interval, 0.050–0.636];  $P = .01$ ); therefore, the 6-month metformin intervention led to a reduction in BMI z score in the prepubertal group. Conversely, the other anthropometric and body composition parameters revealed no significant differences between the interventions at 6 months in any pubertal group (Table 2). No differences were found in the impact of metformin according to the pubertal stage when the interaction time  $\times$  treatment  $\times$  puberty was applied to the entire population ( $P = .41$ ). Concerning sex, there

were no differential effects in boys compared with girls (data not shown).

All subjects kept a moderately HLD pattern (second tertile, ranging from 17 to 32 values of HLD index) at all study times. In addition, we observed no difference in behavior for the experimental groups according to pubertal stage and sex across the study.


### Glucose, Insulin Sensitivity, and Lipid Metabolism

Metformin treatment significantly increased the QUICKI in prepubertal children compared with placebo ( $P = .01$ ) (Table 2); no differences were observed in the impact of metformin according to the pubertal stage when the interaction time  $\times$  treatment  $\times$  puberty was applied to the entire population ( $P = .47$ ). There was no evidence of significant differences in other insulin sensitivity markers at 6 months in either the prepubertal or pubertal group, regardless of treatment. The lipid profile did not change throughout the intervention in any treatment group. Data stratified according to sex exhibited no differences between treatments (data not shown).

### Inflammation and Cardiovascular Risk Biomarkers

After the intervention, the prepubertal group exhibited decreased IFN- $\gamma$  and tPAI-1 concentrations in patients in the metformin group compared with those receiving placebo ( $P = .02$ ;  $P = .04$ , respectively) (Table 3). Leptin and adiponectin concentrations did not change over time in either group; however, the ALR increased in prepubertal children after metformin treatment versus placebo ( $P = .01$ ). Furthermore, pubertal children did not show any changes at the end of the trial in the metformin group versus the placebo group.

Neither ALR, tPAI-1, nor IFN- $\gamma$  exhibited a different impact of metformin according to the pubertal



**FIGURE 1**

Flow diagram of participants. PB, pubertal boys; PG, pubertal girls; PPB, prepubertal boys; PPG, prepubertal girls.

stage when the interaction time  $\times$  treatment  $\times$  puberty was applied to all the population ( $P = .07$ ;  $P = .14$ ;  $P = .06$ , respectively).

Regarding sex, boys had an increased ALR after metformin treatment versus placebo (baseline,  $1.0 \pm 0.1$  to 6 months  $1.7 \pm 0.2$  by metformin vs baseline  $0.7 \pm 0.09$  to 6 months  $0.9 \pm 0.2$  by placebo,  $P = .04$ ), but girls only showed a trend ( $0.7 \pm 0.09$  to  $1.2 \pm 0.1$  by metformin vs  $0.7 \pm 0.09$  to  $0.9 \pm 0.1$  by placebo;  $P = .08$ ). For the remaining outcomes, we observed no differential effects in either sex (data not shown).

### Safety, Adherence, and Doses

Metformin was generally well tolerated. None of the subjects had to stop the intervention because of serious adverse events. Both

experimental groups reported having diarrhea (13% in the metformin group, 9% in the placebo group). Lactic acidosis was not reported in any participant. There were no significantly different changes in any safety parameters between the metformin and placebo groups. The clinical signs did not differ at the end of the intervention in any treatment group.

Adherence was measured by using the following formula:  $([\text{pills ingested} - \text{pills returned}] / \text{pills predicted}) \times 100$ . Good adherence to treatment was reported in most participants ( $89\% \pm 1\%$ ). In terms of doses, all patients received 1 g/d of medication, independent of weight. Considering the different effects of metformin according to pubertal stage, we

considered it appropriate to calculate the doses per body weight of each patient. Thus, prepubertal children took  $19.6 \pm 0.74$  mg metformin/kg body weight versus  $13.4 \pm 0.38$  mg/kg taken by the pubertal children ( $P < .001$ ).

### DISCUSSION

In the present RCT, we recorded a significant reduction in BMI z score after 6 months exclusively in prepubertal children who were obese treated with 1 g/d of metformin, even with no significant improvement in lifestyle according to the HLD index of Manios et al.<sup>27</sup> Metformin has previously been found to be efficacious in childhood obesity, especially in reducing BMI z score,

**TABLE 2** Changes in Anthropometry, Body Composition, Glucose, Insulin Sensitivity, and Lipid Metabolism in Children Who Are Obese According to Pubertal Status

Variable	Prepubertal (Tanner Stage I)				<i>P</i> <sup>a</sup>	Pubertal (Tanner Stages II–V)				<i>P</i> <sup>a</sup>
	Placebo		Metformin			Placebo		Metformin		
	Baseline ( <i>n</i> = 40)	6 mo ( <i>n</i> = 34)	Baseline ( <i>n</i> = 40)	6 mo ( <i>n</i> = 33)		Baseline ( <i>n</i> = 40)	6 mo ( <i>n</i> = 38)	Baseline ( <i>n</i> = 40)	6 mo ( <i>n</i> = 35)	
Adherence, %	86 ± 3		94 ± 2			87 ± 3		91 ± 2		
Height, cm	141.3 ± 1.5	144.6 ± 1.5	140.6 ± 1.6	144.0 ± 1.5	.88	160.5 ± 1.4	162.9 ± 1.3	159.0 ± 1.4	161.5 ± 1.4	.56
Weight, kg	59.9 ± 2.0	60.2 ± 2.2	55.8 ± 2.1	54.0 ± 2.2	.13	80.5 ± 2.4	81.7 ± 2.4	76.9 ± 2.4	77.4 ± 2.5	.56
BMI	29.2 ± 0.6	28.2 ± 0.6	28.2 ± 0.6	26.5 ± 0.7	.19	30.6 ± 0.5	30.2 ± 0.5	29.4 ± 0.5	28.5 ± 0.6	.22 <sup>b</sup>
BMI z score	4.0 ± 0.2	3.4 ± 0.2	3.4 ± 0.2	2.6 ± 0.2	.04	3.2 ± 0.2	3.0 ± 0.2	3.2 ± 0.2	2.8 ± 0.2	.19
Waist perimeter, cm	94.5 ± 1.9	94.6 ± 1.9	89.3 ± 2.0	88.7 ± 2.0	.72	95.4 ± 1.8	94.6 ± 1.9	93.7 ± 1.8	92.9 ± 1.9	.89 <sup>b</sup>
Fat mass, %	38 ± 0.8	37 ± 1.0	37 ± 0.8	35 ± 1.0	.41	37 ± 0.8	37 ± 1.0	38 ± 0.9	37 ± 1.0	.77
Lean mass, %	60 ± 0.9	63 ± 1.1	62 ± 0.9	64 ± 1.2	.52	56 ± 1.5	57 ± 1.5	56 ± 1.7	57 ± 1.7	.38
Fasting glucose, mg/dL	87.1 ± 1.4	84.6 ± 1.7	85.6 ± 1.4	82.9 ± 1.7	.88	86.7 ± 1.0	86.1 ± 1.2	87.7 ± 1.1	86.4 ± 1.3	.63
Fasting insulin, μU/mL	12.2 ± 1.3	12.0 ± 1.4	12.9 ± 1.4	13.4 ± 1.5	.69	20.8 ± 1.8	21.6 ± 1.6	20.0 ± 1.9	20.1 ± 1.8	.79
HOMA-IR	2.6 ± 0.3	2.5 ± 0.3	2.7 ± 0.3	2.8 ± 0.3	.72	4.5 ± 0.4	4.7 ± 0.4	4.4 ± 0.4	4.4 ± 0.4	.73
QUICKI	0.339 ± 0.005	0.332 ± 0.004	0.328 ± 0.005	0.338 ± 0.005	.01	0.311 ± 0.004	0.310 ± 0.004	0.311 ± 0.004	0.314 ± 0.004	.60
TG, mg/dL	68.2 ± 3.8	62.9 ± 3.5	65.1 ± 3.9	58.8 ± 3.5	.92	74.7 ± 4.9	73.6 ± 4.1	69.1 ± 5.6	64.0 ± 4.6	.90
TC, mg/dL	162.0 ± 4.8	157.5 ± 4.0	160.9 ± 4.9	155.3 ± 4.2	.79	158.8 ± 4.4	152.6 ± 4.2	155.1 ± 4.6	155.1 ± 4.4	.17
HDL-C, mg/dL	46.2 ± 1.5	49.6 ± 1.8	43.7 ± 1.6	48.7 ± 1.9	.22	47.8 ± 1.8	47.7 ± 2.1	46.9 ± 1.9	50.3 ± 2.1	.09
LDL-C, mg/dL	99.3 ± 4.7	94.3 ± 4.3	99.5 ± 4.9	93.6 ± 4.4	.83	94.9 ± 3.7	89.1 ± 3.6	90.0 ± 3.8	86.4 ± 3.8	.55
VLDL-C, mg/dL	13.8 ± 0.7	13.0 ± 0.6	12.7 ± 0.8	11.0 ± 0.6	.40	14.6 ± 1.2	12.2 ± 1.0	11.7 ± 1.2	11.3 ± 1.0	.06
Apo A1, mg/dL	130.1 ± 3.8	135.0 ± 4.2	127.8 ± 3.9	136.2 ± 4.2	.44	130.7 ± 3.6	134.2 ± 3.9	135.0 ± 3.8	142.4 ± 4.1	.33
Apo B, mg/dL	70.3 ± 2.9	70.0 ± 3.0	66.1 ± 2.9	69.7 ± 3.0	.28	74.3 ± 4.4	72.1 ± 6.3	83.4 ± 5.0	85.0 ± 7.2	.55

Data are presented as mean ± SEM. All *P* values adjusted by using the Bonferroni correction. Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment for insulin resistance; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; TC, total cholesterol; VLDL-C, very low-density lipoprotein cholesterol.

<sup>a</sup> Differences from placebo at the end of intervention by general linear model for repeated measures (95% confidence interval), *P* < .05.

<sup>b</sup> Analysis of covariance analysis to variables with differences at baseline between treatments (95% confidence interval).

**TABLE 3** Changes in Adipokine Levels, Biomarkers of Inflammation, and Cardiovascular Risk in Children Who Are Obese According to Pubertal Status

Variable	Prepubertal (Tanner Stage I)				<i>P</i> <sup>a</sup>	Pubertal (Tanner Stages II–V)				<i>P</i> <sup>a</sup>
	Placebo		Metformin			Placebo		Metformin		
	Baseline ( <i>n</i> = 40)	6 mo ( <i>n</i> = 34)	Baseline ( <i>n</i> = 40)	6 mo ( <i>n</i> = 33)		Baseline ( <i>n</i> = 40)	6 mo ( <i>n</i> = 38)	Baseline ( <i>n</i> = 40)	6 mo ( <i>n</i> = 35)	
Adiponectin, mg/L	12.4 ± 1.2	13.5 ± 1.3	11.8 ± 1.2	15.4 ± 1.4	.23	7.9 ± 0.8	7.5 ± 0.8	9.4 ± 0.9	10.3 ± 0.8	.20
Leptin, μg/L	15.8 ± 1.1	15.4 ± 1.2	12.2 ± 1.2	10.5 ± 1.3	.08 <sup>b</sup>	15.9 ± 0.9	13.5 ± 1.1	14.7 ± 1.0	12.3 ± 1.3	.98
ALR	0.91 ± 0.1	1.1 ± 0.2	1.0 ± 0.1	1.9 ± 0.2	.01	0.5 ± 0.1	0.7 ± 0.1	0.6 ± 0.1	1.0 ± 0.1	.32
Resistin, μg/L	10.7 ± 0.9	12.8 ± 1.1	11.3 ± 0.9	12.4 ± 1.1	.41	14.1 ± 0.8	13.7 ± 1.3	13.8 ± 0.8	14.2 ± 1.4	.75
IFN-γ, ng/L	11.3 ± 2.0	11.3 ± 1.6	11.5 ± 2.1	5.9 ± 1.7	.02	11.4 ± 1.9	9.1 ± 1.9	10.8 ± 1.9	10.1 ± 1.9	.37
IL-8, ng/L	2.6 ± 0.4	1.7 ± 0.3	2.7 ± 0.4	1.8 ± 0.3	.99	3.9 ± 0.4	1.9 ± 0.2	3.7 ± 0.4	1.6 ± 0.2	.13
CRP, mg/L	3.6 ± 0.4	2.6 ± 0.6	2.7 ± 0.4	3.5 ± 0.6	.22	2.4 ± 0.4	2.6 ± 0.4	2.7 ± 0.4	2.1 ± 0.4	.28
MCP-1, ng/L	201.4 ± 18.2	182.1 ± 11.1	215.0 ± 18.4	179.9 ± 11.3	.94	188.1 ± 8.4	162.0 ± 8.7	173.6 ± 8.8	152.0 ± 9.1	.57
TNF-α, ng/L	8.7 ± 0.6	8.2 ± 0.5	8.6 ± 0.7	6.8 ± 0.5	.15	7.8 ± 0.5	5.0 ± 0.3	8.2 ± 0.5	5.2 ± 0.3	.73
VEGF, ng/L	139.9 ± 12.0	134.5 ± 12.6	148.7 ± 12.8	125.1 ± 13.3	.98	134.7 ± 10.9	97.0 ± 11.3	127.5 ± 11.4	106.2 ± 11.9	.15
MPO, μg/L	142.0 ± 36.9	84.3 ± 12.8	152.1 ± 37.5	81.4 ± 13.0	.59	169.7 ± 44.3	96.4 ± 18.3	169.0 ± 42.3	91.2 ± 17.5	.57
sICAM-1, μg/L	108.7 ± 7.9	90.2 ± 6.5	115.4 ± 8.1	85.2 ± 6.6	.36	101.8 ± 4.5	80.6 ± 3.7	107.3 ± 4.7	87.5 ± 3.9	.81
sVCAM-1, μg/L	723.1 ± 41.9	693.0 ± 37.9	761.6 ± 42.6	708.8 ± 38.5	.74	781.8 ± 30.0	661.3 ± 27.6	796.2 ± 31.3	708.9 ± 28.7	.46
tPAI-1, μg/L	18.8 ± 1.8	21.2 ± 1.9	20.2 ± 1.8	18.5 ± 1.9	.04	37.5 ± 2.6	25.7 ± 2.2	34.2 ± 2.7	22.2 ± 2.3	.79
Ox-LDL, mU/mL	3972 ± 963	3861 ± 882	5163 ± 963	3937 ± 882	.42	3932 ± 574	3730 ± 646	2948 ± 590	2623 ± 664	.74 <sup>b</sup>

Data are presented as mean ± SEM. All *P* values adjusted by using the Bonferroni correction. CRP, C-reactive protein; IL-8, interleukin-8; MCP-1, monocyte chemoattractant protein-1; MPO, myeloperoxidase; Ox-LDL, oxidized low-density lipoprotein; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular adhesion molecule-1; VEGF, vascular endothelial growth factor.

<sup>a</sup> Differences from placebo at the end of intervention by general linear model for repeated measures (95% confidence interval), *P* < .05.

<sup>b</sup> Analysis of covariance analysis to variables with differences at baseline between treatments (95% confidence interval).

the most appropriate and precise internationally accepted body mass parameter for children.<sup>26</sup> Previous investigators have reported similar effects of 1500 to 2000 mg/d after 6 months in prepubertal and pubertal children who are obese.<sup>18,22,28</sup> In the current study, we found no significant change concerning BMI z score in pubertal children who were obese, similar to findings from some RCTs in this population<sup>29–31</sup> but different from other RCTs.<sup>17,32</sup> The diverse results found in the present RCT illustrate the importance of considering puberty in intervention studies of metformin in children who are obese. None of the previous studies used a study design to allow observing a differential response according to pubertal status separately.

A lack of effect of metformin in the pubertal children who were obese might be related to the lower doses used for these subjects (milligrams of metformin per kilograms of body weight), providing dose-dependent efficacy according to body weight. Reviewing the literature, only Mauras et al<sup>21</sup> divided metformin doses into 1000 mg/d for those aged <12 years and 2000 mg/d for those aged ≥2 years; however, their sample size was small, and no differential responses were observed according to the pubertal stage. Nevertheless, we cannot exclude the fact that the failure of a metformin effect in pubertal children could also be due to the physiologic and hormonal changes in that stage. Indeed, puberty is associated with a marked decrease in insulin sensitivity,<sup>33</sup> and an insulin-sensitizing therapy would therefore have to be increased proportionately to observe a similar effect in prepubertal children. Accordingly, future RCTs should consider higher doses of metformin for adolescents to obtain a beneficial effect, taking into account the maximum dosing described for

youngsters aged 10 to 16 years (2000 mg/d).<sup>34</sup>

Regarding the lipid profiles, no significant changes occurred in any pubertal group. Three studies have shown an improvement in some lipid parameters in pubertal subjects who are obese.<sup>17,35,36</sup> However, no changes were observed compared with the placebo intervention by many other studies in patients both prepubertal and pubertal who were obese,<sup>18,21,22,30,37</sup> nor were there any changes in pubertal population only.<sup>16,20,29,32</sup> Hence, the evidence is still unclear and seems to depend on the presence/absence of dyslipidemia.<sup>38</sup>

Furthermore, metformin is considered as an insulin sensitizer, with its pleiotropic actions, and it exerts protective effects on multiple organs, mainly in insulin-targeted tissues such as liver, muscle, and adipose tissues.<sup>39</sup> In the current study, QUICKI, considered for years as an optimal method of determining insulin sensitivity in subjects who are obese, increased only in the prepubertal children. One previous RCT assessed the changes in QUICKI according to a metformin intervention for 6 months in an experimental group comprising both prepubertal and pubertal children who were obese, but no effects were obtained.<sup>22</sup> Moreover, a significant increase has only been shown to date in pubertal children who are obese.<sup>32,36</sup>

A significant improvement in the ALR was observed in the prepubertal children after taking metformin. The ALR is considered a potential surrogate marker for cardiometabolic disease.<sup>40</sup> Similar results have been reported by previous investigators in children<sup>22</sup> and adolescents who are obese.<sup>17,22</sup> However, we found no effects of metformin on plasma adipokine levels. In reviewing previous studies of subjects who are obese aged 4 to 19 years, levels of adiponectin did not change

during the metformin intervention compared with placebo,<sup>16,17,19,20,22</sup> neither did leptin levels, which were found to be decreased only in 2 studies.<sup>32,35</sup> Freemark and Bursey<sup>32</sup> reported a decrease in pubertal girls who were obese but not in their male peers.

A variety of proinflammatory mediators associated with cardiometabolic dysfunction are known to be influenced by childhood obesity.<sup>22</sup> We have reported for the first time a decline in INF- $\gamma$  plasma concentrations after metformin treatment over 6 months in prepubertal children who are obese only. There are no studies to date in humans that assessed changes in INF- $\gamma$  in subjects who are obese. However, it has been reported that metformin exerted its immunosuppressive effect by inhibiting the expression of proinflammatory mediators as IFN- $\gamma$  both in a macrophage cell line (RAW267.4) and in animal models of multiple sclerosis.<sup>41</sup> This finding may be interesting enough to warrant investigation of other actions of metformin pathways. Similarly, tPAI-1 is a principal physiologic inhibitor of fibrinolysis and a relevant marker of inflammation and prothrombosis.<sup>42</sup> Thus far, only Mauras et al<sup>21</sup> have evaluated the effects of metformin on tPAI-1 concentrations, and they observed no changes by metformin and no differences according to pubertal stage. The current RCT is the first study to report an influence of metformin on tPAI-1 reduction in pediatric patients who are obese and only in the prepubertal group. CRP was not modified in the current study in either pubertal group after treatment. Different investigators have evaluated this inflammatory biomarker after metformin interventions, but none of them found changes.<sup>16,19–22</sup> Another well-known inflammation biomarker, TNF- $\alpha$ , has been studied only in 2 RCTs similar to ours.<sup>19,20</sup>

Only Evia-Viscarra et al<sup>19</sup> observed changes in the variances of serum TNF- $\alpha$  concentration over 3 months in pubertal children who are obese. In terms of the other cardiovascular risk and inflammatory biomarkers, they had not been analyzed to date in children who are obese. However, changes in these biomarkers were not found in the current study. Evidence regarding some of these biomarkers has only been achieved in the adult population.<sup>7-14</sup> Thus, more studies are needed to elucidate the effects of metformin on inflammatory biomarkers in the early onset of obesity.

Our study has several limitations, including the difficulty in assessing treatment compliance by using pill count, as well as lifestyle changes in the children. In addition, although the index proposed by Manios et al<sup>27</sup> has been validated for primary school children and was carefully revised, it did not include the intake of some routine foods in the Spanish diet (eg, olive oil), which may influence dietary habits. Furthermore, we controlled for medication taken by monitoring the delivery and return of pill bottles; however, we are aware

that this strategy does not ensure accuracy regarding information on intervention compliance.

## CONCLUSIONS

The onset of childhood obesity may begin early in life. This fact clearly has important implications for the future development of cardiovascular disease in children who are obese and in young people. Better pharmacologic strategies are needed to reduce cardiovascular risk in this population. In the present RCT, prepubertal children had a decreased BMI z score and improvements in other parameters related to obesity after undergoing metformin treatment for 6 months, but pubertal children did not. Hence, puberty is an important physiologic stage that plays a key role in the differential response to metformin that should be explored further, particularly in terms of the dose-effect relationships.

## ACKNOWLEDGMENTS

The authors acknowledge the Spanish Ministry of Health, Social

and Equality, General Department for Pharmacy and Health Products for financing this study and the Instituto de Salud Carlos III-Fondo de Investigación Sanitaria (FONDOS FEDER), Redes temáticas de investigación cooperativa RETIC (Red SAMID RD12/0026/0015). They also thank M. Cruz Rico for performing the biochemical analysis. This article will be part of María Belén Pastor Villaescusa's doctorate degree, which is being performed within the "Nutrition and Food Sciences Program" at the University of Granada.

## ABBREVIATIONS

ALR: adiponectin-leptin ratio  
CV: coefficient of variation  
HLD: healthy lifestyle/diet  
IFN- $\gamma$ : interferon- $\gamma$   
PAI-1: plasminogen activator inhibitor-1  
QUICKI: quantitative insulin sensitivity check index  
RCT: randomized controlled trial  
T2DM: type 2 diabetes mellitus  
TNF- $\alpha$ : tumor necrosis factor  $\alpha$

Dr Pastor-Villaescusa was responsible for all the data and sample collection, as well as for the development of the food frequency questionnaire (FFQ) and a physical activity survey in Granada; she also wrote the manuscript; Dr Cañete designed the study, performed the data and sample acquisition, and administered the FFQ and a physical activity survey to all participants in Reina Sofía Hospital (Córdoba); Dr Caballero-Villarraso designed the study and obtained grant funding; Mr Hoyos was responsible for child recruitment and randomized controlled trial (RCT) management in the Virgen de las Nieves University Hospital (Granada); Ms Latorre and Dr Vázquez-Cobela performed the data and sample acquisition and developed the FFQ in the Lozano Blesa University Hospital (Zaragoza) and in the Clinic University Hospital of Santiago (Santiago de Compostela), respectively; Dr Plaza-Díaz collaborated in the data analysis, as well as its interpretation and discussion; Dr Maldonado was responsible for, and coordinator of, child recruitment and RCT management in the Virgen de las Nieves University Hospital (Granada); Drs Bueno and Leis were responsible for, and coordinator of, child recruitment and RCT management in the Lozano Blesa University Hospital (Zaragoza) and in the Clinic University Hospital of Santiago (Santiago de Compostela), respectively; Dr Gil designed the study and obtained grant funding, was involved in the data interpretation and discussion, and reviewed and edited the manuscript; Dr Cañete is the trial promoter, designed the study, and obtained grant funding; and Dr Aguilera created the sampling and analysis protocols, supervised the data collection, was involved in the data interpretation and discussion, and critically reviewed and edited the manuscript. All authors read and approved the final manuscript and take full responsibility for the manuscript content.

This trial has been registered in the European Clinical Trials Database (identifier 2010-023061-21).

**DOI:** <https://doi.org/10.1542/peds.2016-4285>

Accepted for publication Mar 21, 2017

Address correspondence to Concepción María Aguilera Garcia, PhD, Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology, Center of Biomedical Research, Laboratory 123, University of Granada, Avenida del Conocimiento s/n, 18006 Armilla, Granada, Spain. E-mail: caguiler@ugr.es

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).



**FINANCIAL DISCLOSURE:** The authors have indicated they have no financial relationships relevant to this article to disclose.

**FUNDING:** Funded by the Spanish Ministry of Health, Social and Equality, General Department for Pharmacy and Health Products (codes: EC10-243, Dr Cañete, Reina Sofía Hospital, Córdoba; EC10-056, Dr Gil, University of Granada and Virgen de las Nieves University Hospital, Granada; EC10-281, Dr Leis, Clinic University Hospital of Santiago, Santiago de Compostela; and EC10-227, Dr Bueno, Lozano Blesa University Clinical Hospital, Zaragoza).

**POTENTIAL CONFLICT OF INTEREST:** The authors have indicated they have no potential conflicts of interest to disclose.

**COMPANION PAPER:** A companion to this article can be found online at [www.pediatrics.org/cgi/doi/10.1542/peds.2017-1205](http://www.pediatrics.org/cgi/doi/10.1542/peds.2017-1205).

## REFERENCES

- Centers for Disease Control and Prevention (CDC). Self-reported influenza-like illness during the 2009 H1N1 influenza pandemic—United States, September 2009–March 2010. *MMWR Morb Mortal Wkly Rep*. 2011;60(2):37–41
- Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. *Pediatrics*. 1999;103(6 pt 1):1175–1182
- Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. *N Engl J Med*. 2004;350(23):2362–2374
- Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346(6):393–403
- Kelly AS, Fox CK, Rudser KD, Gross AC, Ryder JR. Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations. *Int J Obes (Lond)*. 2016;40(7):1043–1050
- Golay A. Metformin and body weight. *Int J Obes*. 2008;32(1):61–72
- De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. *J Intern Med*. 2005;257(1):100–109
- Skrha J, Prázný M, Hilgertová J, Kvasnicka J, Kalousová M, Zima T. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. *Eur J Clin Pharmacol*. 2007;63(12):1107–1114
- Ersoy C, Kiyici S, Budak F, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. *Diabetes Res Clin Pract*. 2008;81(1):56–60
- Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. *Cardiovasc Diabetol*. 2012;11:64
- Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. *Am Heart J*. 2007;153(3):445.e1–445.e6
- Lima LM, Wiernsperger N, Kraemer-Aguar LG, Bouskela E. Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. *Clinics (Sao Paulo)*. 2009;64(5):415–420
- Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. *Diabetes Res Clin Pract*. 2011;93(1):56–62
- Esteghamati A, Eskandari D, Mirmiranpour H, et al. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. *Clin Nutr*. 2013;32(2):179–185
- McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. *JAMA Pediatr*. 2014;168(2):178–184
- Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. *Pediatr Diabetes*. 2008;9(6):567–576
- Clarson CL, Mahmud FH, Baker JE, et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. *Endocrine*. 2009;36(1):141–146
- Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. *Diabetes*. 2011;60(2):477–485
- Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jiménez E, et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. *J Pediatr Endocrinol Metab*. 2012;25(1–2):41–49
- Gómez-Díaz RA, Talavera JO, Pool EC, et al. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. *Metabolism*. 2012;61(9):1247–1255
- Mauras N, DelGiorno C, Hossain J, et al. Metformin use in children with obesity and normal glucose tolerance—effects on cardiovascular markers and intrahepatic fat. *J Pediatr Endocrinol Metab*. 2012;25(1–2):33–40
- Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. *J Clin Endocrinol Metab*. 2013;98(1):322–329
- Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity,

- and stages of puberty. *Arch Dis Child*. 1976;51(3):170–179
24. Pastor-Villaescusa B, Caballero-Villarraso J, Cañete MD, et al. Evaluation of differential effects of metformin treatment in obese children according to pubertal stage and genetic variations: study protocol for a randomized controlled trial. *Trials*. 2016;17(1):323
  25. Ministry of Health of the Spanish Government. Spanish strategy for nutrition, physical activity and prevention of obesity (NAOS Strategy). AECOSAN NAOS Strategy's NAOS Pyramid (Ministry of Health of the Spanish Government). Available at: [www.aecosan.msssi.gob.es/en/AECOSAN/web/nutricion/subseccion/piramide\\_NAOS.htm](http://www.aecosan.msssi.gob.es/en/AECOSAN/web/nutricion/subseccion/piramide_NAOS.htm). Accessed March 9, 2017
  26. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ*. 2000;320(7244):1240–1243
  27. Manios Y, Moschonis G, Papandreou C, et al; 'Healthy Growth Study' group. Revised Healthy Lifestyle-Diet Index and associations with obesity and iron deficiency in schoolchildren: The Healthy Growth Study. *J Hum Nutr Diet*. 2015;28(suppl 2):50–58
  28. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. *J Clin Endocrinol Metab*. 2006;91(6):2074–2080
  29. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. *J Pediatr*. 2008;152(6):817–822
  30. Wiegand S, l'Allemand D, Hübel H, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. *Eur J Endocrinol*. 2010;163(4):585–592
  31. van der Aa MP, Elst MA, van de Garde EM, van Mil EG, Knibbe CA, van der Vorst MM. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. *Nutr Diabetes*. 2016;6(8):e228
  32. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. *Pediatrics*. 2001;107(4). Available at: [www.pediatrics.org/cgi/content/full/107/4/e55](http://www.pediatrics.org/cgi/content/full/107/4/e55)
  33. Kelsey MM, Zeitler PS. Insulin resistance of puberty. *Curr Diab Rep*. 2016;16(7):64
  34. Brufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M. Use of metformin in pediatric age. *Pediatr Diabetes*. 2011;12(6):580–588
  35. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. *Metabolism*. 2001;50(12):1457–1461
  36. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. *J Pediatr Endocrinol Metab*. 2008;21(4):339–348
  37. Marques P, Limbert C, Oliveira L, Santos MI, Lopes L. Metformin effectiveness and safety in the management of overweight/obese nondiabetic children and adolescents: metabolic benefits of the continuous exposure to metformin at 12 and 24 months [published online ahead of print February 19, 2016]. *Int J Adolesc Med Health*. doi:10.1515/ijamh-2015-0110
  38. Fontbonne A, Charles MA, Juhan-Vague I, et al; BIGPRO Study Group. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. *Diabetes Care*. 1996;19(9):920–926
  39. Yang X, Xu Z, Zhang C, Cai Z, Zhang J. Metformin, beyond an insulin sensitizer, targeting heart and pancreatic  $\beta$  cells [published online ahead of print October 1, 2016]. *Biochim Biophys Acta*. doi:10.1016/j.bbadis.2016.09.019
  40. Kotani K, Sakane N. Leptin:adiponectin ratio and metabolic syndrome in the general Japanese population. *Korean J Lab Med*. 2011;31(3):162–166
  41. Nath N, Khan M, Paintlia MK, Singh I, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis [published correction appears in *J Immunol*. 2009;183(5):3551]. *J Immunol*. 2009;182(12):8005–8014
  42. Mauras N, Delgiorno C, Kollman C, et al. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. *J Clin Endocrinol Metab*. 2010;95(3):1060–1068

## Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial

Belén Pastor-Villaescusa, M. Dolores Cañete, Javier Caballero-Villarraso, Raúl Hoyos, Miriam Latorre, Rocío Vázquez-Cobela, Julio Plaza-Díaz, José Maldonado, Gloria Bueno, Rosaura Leis, Ángel Gil, Ramón Cañete and Concepción M. Aguilera  
*Pediatrics* 2017;140;; originally published online June 12, 2017;  
DOI: 10.1542/peds.2016-4285

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="/content/140/1/e20164285.full.html">/content/140/1/e20164285.full.html</a>
<b>Supplementary Material</b>	Supplementary material can be found at: <a href="/content/suppl/2017/06/08/peds.2016-4285.DCSupplemental.html">/content/suppl/2017/06/08/peds.2016-4285.DCSupplemental.html</a>
<b>References</b>	This article cites 41 articles, 8 of which can be accessed free at: <a href="/content/140/1/e20164285.full.html#ref-list-1">/content/140/1/e20164285.full.html#ref-list-1</a>
<b>Citations</b>	This article has been cited by 2 HighWire-hosted articles: <a href="/content/140/1/e20164285.full.html#related-urls">/content/140/1/e20164285.full.html#related-urls</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Endocrinology</b> <a href="/cgi/collection/endocrinology_sub">/cgi/collection/endocrinology_sub</a> <b>Obesity</b> <a href="/cgi/collection/obesity_new_sub">/cgi/collection/obesity_new_sub</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="/site/misc/Permissions.xhtml">/site/misc/Permissions.xhtml</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="/site/misc/reprints.xhtml">/site/misc/reprints.xhtml</a>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial**

Belén Pastor-Villaescusa, M. Dolores Cañete, Javier Caballero-Villarraso, Raúl Hoyos, Miriam Latorre, Rocío Vázquez-Cobela, Julio Plaza-Díaz, José Maldonado, Gloria Bueno, Rosaura Leis, Ángel Gil, Ramón Cañete and Concepción M. Aguilera  
*Pediatrics* 2017;140;; originally published online June 12, 2017;  
DOI: 10.1542/peds.2016-4285

The online version of this article, along with updated information and services, is located on the World Wide Web at:  
</content/140/1/e20164285.full.html>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

